Tumor necrosis factor-α-converting enzyme (TACE) levels in periodontal diseases

Journal of Dental Research

Volumn 87, Issue 3, 2008, Pages 273-277

  Bostanci, N ^a   Emingil, G ^b   Afacan, B ^b   Han, B ^b   Ilgenli, T ^b   Atilla, G ^b   Hughes, F J ^a   Belibasakis, G N ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b EGE UNIVERSITY   (Turkey)

Author keywords

Bone resorption; Gingival crevicular fluid; Periodontal diseases; RANKL; TACE

Indexed keywords

ADAM PROTEIN; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; SECRETASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHEMISTRY; CHRONIC DISEASE; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; GINGIVA BLEEDING; GINGIVITIS; HUMAN; KIDNEY TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; OSTEOLYSIS; PERIODONTAL DISEASE; PERIODONTITIS; PERIODONTIUM;

ADAM PROTEINS; ADOLESCENT; ADULT; ALVEOLAR BONE LOSS; AMYLOID PRECURSOR PROTEIN SECRETASES; CHRONIC DISEASE; ENZYME INHIBITORS; FEMALE; GINGIVAL CREVICULAR FLUID; GINGIVAL HEMORRHAGE; GINGIVITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PERIODONTAL ATTACHMENT LOSS; PERIODONTAL POCKET; PERIODONTITIS; PERIODONTIUM; RANK LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41149165731     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910808700311     Document Type: Article

References (35)

1. Armitage GC (1999). Development of a classification system for periodontal diseases and conditions. Ann Periodontal 4:1-6.
2. Black RA (2002). Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 34:1-5.
3. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. (1997). A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells. Nature 385:729-733.
4. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Toz H, et al. (2007a). Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontal 34:370-376.
5. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Toz H, et al. (2007b). Differential expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin mRNA in periodontal diseases. J Periodontal Res 42:287-293.
6. Burrage PS, Brinckerhoff CE (2007). Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr Drug Targets 8:293-303.
7. Chung RM, Grbic JT, Lamster IB (1997). Interleukin-8 and beta-glucuron-idase in gingival crevicular fluid. J Clin Periodontal 24:146-152.
8. Crotti T, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M, et al. (2003). Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 38:380-387.
9. Garlet GP, Martins W Jr, Fonseca BA, Ferreira BR, Silva JS (2004). Matrix metalloproteinases, their physiological inhibitors and osteoclast factors are differentially regulated by the cytokine profile in human periodontal disease. J Clin Periodontal 31:671-679.
10. Han X, Kawai T, Eastcott JW, Taubman MA (2006). Bacterial-responsive B lymphocytes induce periodontal bone resorption. J Immunol 176:625-631.
11. Horiki M, Nakase T, Myoui A, Sugano N, Nishii T, Tomita T, et al. (2004). Localization of RANKL in osteolytic tissue around a loosened joint prosthesis. J Bone Miner Metab 22:346-351.
12. Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY, et al. (2006). B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 169:987-998.
13. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. (1999). Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309.
14. Lamster IB, Holmes LG, Gross KB, Oshrain RL, Cohen DW, Rose LF, et al. (1994). The relationship of beta-glucuronidase activity in crevicular fluid to clinical parameters of periodontal disease. Findings from a multicenter study. J Clin Periodontal 21:118-127.
15. Liu D, Xu JK, Figliomeni L, Huang L, Pavlos NJ, Rogers M, et al. (2003). Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int J Mol Med 11:17-21.
16. Lu HK, Chen YL, Chang HC, Li CL, Kuo MY (2006). Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. J Periodontal Res 41:354-360.
17. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, et al. (1999). Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274:13613-13618.
18. Mizuno A, Kanno T, Hoshi M, Shibata O, Yano K, Fujise N, et al. (2002). Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab 20:337-344.
19. Mogi M, Otogoto J, Ota N, Togari A (2004). Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 83:166-169.
20. Moss ML, Bartsch JW (2004). Therapeutic benefits from targeting of ADAM family members. Biochemistry 43:7227-7235.
21. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al. (1997). Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385:733-736; erratum in Nature 386:738, 1997.
22. Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Yamashita T, et al. (2007). Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol 178:192-200.
23. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, et al. (2000). Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275:768-775.
24. Nishijima Y, Yamaguchi M, Kojima T, Aihara N, Nakajima R, Kasai K (2006). Levels of RANKL and OPG in gingival crevicular fluid during orthodontic tooth movement and effect of compression force on releases from periodontal ligament cells in vitro. Orthod Craniofac Res 9:63-70.
25. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, et al. (2000). Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 275:14608-14614.
26. Schlondorff J, Lum L, Blobel CP (2001). Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J Biol Chem 276:14665-14674.
27. Taubman MA, Valverde P, Han X, Kawai T (2005). Immune response: the key to bone resorption in periodontal disease. J Periodontal 76(11 Suppl):2033S-2041S.
28. Taubman MA, Kawai T, Han X (2007). The new concept of periodontal disease pathogenesis requires new and novel therapeutic strategies. J Clin Periodontal 34:367-369.
29. Teitelbaum SL (2000). Bone resorption by osteoclasts. Science 289:1504-1508.
30. Teng YT (2006). Protective and destructive immunity in the periodontium: Part 2 - T-cell-mediated immunity in the periodontium. J Dent Res 85:209-219; erratum in J Dent Res 85:384, 2006.
31. Teng YT, Nguyen H, Gao X, Kong YY, Gorczynski RM, Singh B, et al. (2000). Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 106:59-67.
32. Uitto VJ, Overall CM, McCulloch C (2003). Proteolytic host cell enzymes in gingival crevice fluid. Periodontal 2000 31:77-104.
33. Vernal R, Chaparro A, Graumann R, Puente J, Valenzuela MA, Gamonal J (2004). Levels of cytokine receptor activator of nuclear factor kappaB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. J Periodontal 75:1586-1591.
34. Weitzmann MN, Cenci S, Rifas L, Haug J, Dipersio J, Pacifici R (2001). T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res 16:328-337.
35. Zhang Z, Cork J, Ye P, Lei D, Schwarzenberger PO, Summer WR, et al. (2000). Inhibition of TNF-alpha processing and TACE-mediated ectodomain shedding by ethanol. J Leukoc Biol 67:856-862.